Blood Advances (Sep 2019)

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

  • Mohamad A. Meybodi,
  • Wenhao Cao,
  • Leo Luznik,
  • Asad Bashey,
  • Xu Zhang,
  • Rizwan Romee,
  • Wael Saber,
  • Mehdi Hamadani,
  • Daniel J. Weisdorf,
  • Haitao Chu,
  • Armin Rashidi

Journal volume & issue
Vol. 3, no. 17
pp. 2581 – 2585

Abstract

Read online

Abstract: HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.